SCHEMBL3810697

SCHEMBL3810697

N#Cc1cccc(C(c2ccnc(N)n2)C(c2cccnc2)c2cccnc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.42
CHRNB2 P17787 2/20 0.40
CHRNA5 P30532 2/20 0.40
CHRNA4 P43681 2/20 0.40
VNN1 O95497 1/20 0.40
KCNA5 P22460 6/20 0.40
KCNH2 Q12809 2/20 0.40
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
KCNE1 P15382 1/20 0.38
KCNQ1 P51787 1/20 0.38
KCND3 Q9UK17 1/20 0.38
ATR Q13535 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3887314 1.00 CYP19A1 (0.42) CYP19A1CHRNB2CHRNA5CHRNA4VNN1
SCHEMBL3818719 1.00 CYP19A1 (0.42) CYP19A1CHRNB2CHRNA5CHRNA4VNN1
SCHEMBL13716418 0.93 CYP19A1 (0.39) CYP19A1CHRNB2CHRNA5CHRNA4VNN1
SCHEMBL3886787 0.93 KCNA5 (0.45) CYP19A1CHRNB2CHRNA5CHRNA4VNN1
SCHEMBL1378282 0.88 CYP19A1 (0.53) CYP19A1CHRNB2CHRNA5CHRNA4KCNA5
SCHEMBL3899464 0.87 VNN1 (0.43) CYP19A1CHRNB2CHRNA5CHRNA4VNN1
SCHEMBL1379277 0.87 CYP19A1 (0.55) CYP19A1CHRNB2CHRNA5CHRNA4KCNA5
SCHEMBL1378651 0.86 KCNA5 (0.47) CYP19A1CHRNB2CHRNA5CHRNA4VNN1
SCHEMBL1378917 0.83 CYP19A1 (0.48) CYP19A1KCNA5KCNH2ALDH1A1MAPK1
SCHEMBL1383218 0.83 VNN1 (0.45) CYP19A1CHRNB2CHRNA5CHRNA4VNN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776355-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2013-06-12 EP claimed
US-20060030595-A1 (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias MERCK SHARP & DOHME LLC 2006-02-09 US claimed
EP-1776355-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2013-06-12 EP disclosed
EP-1776355-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2013-06-12 EP disclosed
EP-1776355-A4 POTASSIUM CHANNEL INHIBITORS MERCK & CO INC (US) 2009-08-12 EP disclosed
US-7569589-B2 Potassium channel inhibitors MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569589-B2 Potassium channel inhibitors MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569589-B2 Potassium channel inhibitors MERCK & CO., INC. (US) 2009-08-04 US disclosed
EP-1776355-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2007-04-25 EP disclosed
WO-2006028590-A1 1,1,2,2-TETRA (HETERO) ARYLETHANES OR 1,1,2-TRI (HETERO) ARYL-2-HETEROCYCLYLETHANES AS POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2006-03-16 WO disclosed
WO-2006014877-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2006-02-09 WO disclosed
US-20060030595-A1 (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias MERCK SHARP & DOHME LLC 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030595-A1 (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias KCNN2, KCNJ2, KCNH2 CYP19A1 4696/4885CHRNB2 799/4885CHRNA5 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.